

Electronic Supplementary Information

An Investigation Into the Anti-HIV Activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U) and 2',3'- dideoxyuridine (ddU) Phosphoramidate 'ProTide' Derivatives

Youcef Mehellou¹, Jan Balzarini², and Christopher McGuigan^{1,*}

Experimental

General

All experiments involving water-sensitive compounds were carried out under dry conditions. The solvents used were dry and used as purchased from Aldrich. All the glassware was oven-dried at 130°C for several hours and allowed to cool under a stream of dry nitrogen.

Thin-Layer Chromatography (TLC) was performed using precoated, aluminium-backed silica gel plates (60 F-54, 0.2mm thickness; supplied by E Merck AG, Darmstadt, Germany). Visualisation of the plates was achieved using an ultra-violet (UV) lamp.

Glass columns were slurry-packed in the appropriate eluant under pressure with silica gel, 60A, 40-60µm, (Phase Separations Ltd, Deeside, Clwyd, UK). Samples were applied as a concentrated solution in the same eluant or pre-absorbed on silica gel. Fractions

containing the product were identified by TLC, pooled and the solvent was removed *in vacuo*.


^1H , ^{13}C NMR spectra were recorded on a Bruker Avance 500 MHz spectrometer and autocalibrated to the deuterated solvent reference peak. The following abbreviations are used in the assignment of NMR signals: *s* (singlet), *d* (doublet), *t* (triplet), *q* (quartet), *m* (multiplet).

HPLC analytical investigations were conducted on a Varian Prostar instrument (LC work station, Varian prostar 355 LC detector) using a Polaris C18-A 10 μm column; eluant was performed using a mobile phase consisting of a water/acetonitrile gradient.

Low resolution mass spectra were run on a microTOFLC Bruker Daltonics spectrometer in electropositive mode.

Chemistry

Synthesis of d4U and ddU



Reagents and Conditions: (a) MeSO_2Cl , Pyr, RT (b) Aq.NaOH, MeOH, Reflux (c) NaH, DMF, 100 $^\circ\text{C}$ (d) H_2 , 10% Pd/C, overnight

1-[2,6-dioxo-bicyclo[3.2.0]hept-3-yl]-1*H*-pyrimidine-2,4-dione (2). To a stirred solution of 2'-deoxyuridine (2.00g, 21.91mmol) in anhydrous pyridine (30mL), methanesulfonyl chloride (2.55mL, 65.73mmol) was added drop-wise at 0 $^\circ\text{C}$ under N_2 , and the resulting solution was stirred for a further 30min at room temperature. The solvent was removed *in vacuo* and the residue was washed with ice-cold water (15mL). The resulting brownish solid and aqueous sodium hydroxide (4.4g, 109mmol) in 100mL

of methanol were heated under gentle reflux (88°C) for 2hr. The resulting solution was cooled, neutralized with 35ml of 2N HCl (pH ~ 7) and then concentrated to dryness under reduced pressure. The residue was then extracted with boiling acetone (100mL x 4) and the solvent from the combined extracts was removed under high vacuum giving a crude product which was then purified by flash column chromatography using 5% methanol in dichloromethane as an eluant. This gave the desired compound as a white solid (1.28g, 51%). **¹H NMR** (*d*₆-DMSO): δ 11.24 (1H, *bs*, NH), 7.88 (1H, *d*, *J* = 8.08Hz, H-6), 6.09 (1H, *d*, *J* = 8.10Hz, H-1'), 5.64 (1H, *d*, *J* = 8.08Hz, H-5), 4.26 (1H, *bs*, H-3'), 4.06 (1H, *q*, *J* = 10.29Hz, H-4'), 3.87 (2H, *dd*, *J* = 5.15Hz, *J* = 11.01Hz, H-5'), 2.58-2.64 (2H, *m*, H-2'). **¹³C NMR** (*d*₆-DMSO; 500 MHz): δ 163.16 (C=O), 150.51 (C=O), 141.30 (C-6), 101.48 (C-5), 83.95 (C-4'), 83.84 (C-1'), 68.45 (C-3'), 42.14 (C-5'), 40.58 (C-2').

1-(5-Hydroxymethyl-2,5-dihydro-furan-2-yl)1H-pyrimidine-2,4-dione (3, d4U).

Sodium hydride (60% dispersion in mineral oil: 0.75g, 44.28 mmol) was added to a stirred solution of 1-[2,6-dioxa-bicycol[3.2.0]hept-3-yl]-1H-pyrimidine-2,4-dione(2) (0.97g, 14.28mmol) in anhydrous *N,N*-dimethylformamide (25ml) at room temperature and under N₂. After 5mins, the reaction mixture was heated in an oil bath at 100°C for 4hr. After another 2hrs, when TLC [DCM:MeOH, 9:1] revealed that no starting material remained, the mixture was cooled and the solvent was removed *in vacuo*. The resulting residue was dissolved in methanol (20mL), cooled at 0°C and neutralized (pH~7) by cautious addition of HCl (1N). The solvent was removed under reduced pressure and the crude was purified by flash chromatography using as an eluant DCM:MEOH (9/1). The appropriate fractions were combined and the solvent was removed *in vacuo* affording a brownish solid (0.42g, 43%). **¹H NMR** (*d*₆-DMSO): δ 11.29 (1H, *bs*, NH), 7.74 (1H, *d*, *J* = 8.08Hz, H-6), 6.82 (1H, *m*, H-1'), 6.40 (1H, *t*, *J* = 1.78Hz, H-2'), 5.92 (1H, *t*, *J* = 1.78Hz, H-3'), 5.59 (1H, *d*, *J* = 8.08Hz, H-5), 4.97 (1H, *t*, *J* = 5.39Hz, 5'-OH), 4.78 (2H, *m*, H-4'), 3.59 (2H, *dd*, *J* = 4.95Hz, *J* = 8.59Hz, H-5'). **¹³C NMR** (*d*₆-DMSO): δ 163.20 (C=O), 150.77 (C=O), 141.07 (C-6), 135.05 (C-3'), 125.73 (C-2'), 101.52 (C-5), 89.08 (C-1'), 87.38 (C-4'), 62.24 (C-5'). **HPLC** (H₂O/CH₃CN from 100/0 to 0/100 in 20min): RT 7.95 min. **ESI MS** *m/z* (positive) 233.081 [M+Na].

1-(5-Hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione (4, ddU). 2',3'-didehydro-2',3'-dideoxyuridine (3.2g, 15.22mmol, 1eq.) was dissolved in MeOH (100mL) and 10% Pd/C (0.809mg) was added. Hydrogen gas was introduced into the reaction flask, and the contents were left stirring at room temperature for 5.5hrs. The reaction mixture was filtered through a Celite pad and the solvent was removed. The residue was purified by chromatography using MeOH in chloroform (4:96) as an eluant and the appropriate fractions were collected and the solvent was removed to give the desired product as a white solid in a 75.86% yield (2.45g). ¹H NMR (*d*₆-DMSO): δ 11.27 (1H, *bs*, NH), 7.94 (1H, *d*, *J* = 8.17Hz, H-6), 5.94 (1H, *q*, *J* = 6.82Hz, H-1'), 5.58 (1H, *d*, *J* = 8.17Hz, H-5), 5.05 (1H, *t*, *J* = 5.35Hz, 5'-OH), 4.02 (1H, *m*, H-4'), 3.50-3.70 (2H, *m*, H-5'), 1.91-1.98 (2H, *m*, H-2'), 1.82 (2H, *m*, H-3'). ¹³C NMR (*d*₆-DMSO): δ 163.22 (C=O), 150.40 (C=O), 140.58 (C-6), 101.01 (C-5), 85.13 (C-1'), 81.52 (C-4'), 62.04 (C-5'), 31.79 (C-2'), 24.82 (C-3').

Synthesis of d4U and ddU Phosphoramidates

(S)-methyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (1a). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and phenyl-L-alanine methyl ester phosphorochloridate (263.8mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 82mg of the title compound as a yellowish oil (39%). ³¹P NMR (CDCl₃): δ 3.50, 3.40. ¹H NMR (CDCl₃): δ 8.03 (1H, *bs*, NH), 7.41 (1H, *d*, *J* = 8.65Hz, H-6), 7.06-7.29 (5H, *m*, Ph), 6.92 (1H, *m*, H-1'), 6.23 (1H, *d*, *J* = 8.65Hz, H-5), 5.85 (1H, *m*, H-2'), 5.63 (1H, *m*, H-3'), 5.02 (1H, *m*, H-4'), 4.54 (1H, *s*, NH), 4.27-4.32 (1H, *dd*, *J* = 11.41Hz, H-5'), 4.17-4.21 (1H, *dd*, *J* = 11.41Hz, H-5'), 3.96 (1H, *m*, CH), 3.62-3.70 (3H, *m*, OCH₃), 1.31 (3H, *m*, CH₃).

(S)-methyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)-propanoate (1b). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and 1-naphthyl L-alanine methyl ester phosphorochloridate (311mg,

0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (98:2) as an eluant to afford 51.2mg (21%) of the title compound as a yellowish oil. ³¹P NMR (CDCl₃): δ 3.25, 2.78. ¹H NMR (CDCl₃): δ 8.62 (1H, *bs*, NH), 7.79 (1H, *t*, *J* = 8.75Hz, H-6), 7.12-7.66 (7H, *m*, Ar), 6.89 (1H, *m*, H-1'), 5.81 (1H, *m*, H2'), 5.68 (1H, *m*, H-3'), 5.47 (1H, *q*, *J* = 8.75Hz, H-5), 4.92 (1H, *m*, H-4'), 4.34 (1H, *bs*, NH), 3.95 (2H, *m*, H-5'), 3.62 (1H, *m*, CH), 3.40 (3H, *s*, CH₃), 1.20 (3H, *dd*, *J* = 7.01Hz, *J* = 11.32Hz, CH₃). **ESI MS** *m/z* (positive) 524.167 [M+Na]. **HPLC** (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 9.71, 9.95 min (1:2).

(S)-ethyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (1c). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and phenyl-L-alanine ethyl ester phosphorochloridate (208mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 55.8mg of the title compound as a white solid (43%). ³¹P NMR (CDCl₃): δ 2.90, 2.50. ¹H NMR (CDCl₃): δ 8.87 (1H, *bs*, NH), 7.40 (1H, *d*, *J* = 8.08Hz, H-6), 7.05-7.27 (5H, *m*, Ar), 6.93 (1H, *m*, H-1'), 6.25 (1H, *m*, H-2'), 5.31 (1H, *m*, H-3'), 5.54 (1H, *d*, *J* = 8.08Hz, H-5), 4.95 (1H, *s*, NH), 4.23 (2H, *m*, CH₂), 4.08 (2H, *m*, H-5'), 3.93 (1H, *m*, CH), 1.22 (3H, *q*, *J* = 7.03Hz, CH₃), 1.16 (3H, *m*, CH₃). ¹³C NMR (CDCl₃): δ 140.10 (C6), 133.63, 133.37 (C3'), 129.84, 129.80 (C3''), 127.24, 126.99 (C2'), 125.16 (C4''), 119.95, 119.91, 119.88, 119.84 (C2''), 102.77, 102.59 (C5), 89.92 (C1'), 84.93, 84.86, 84.79 (C4'), 77.28, 77.03, 76.77 (C5'), 61.78, 61.73 (CH₂), 50.32, 50.19 (CH), 21.05, 20.91 (CH₃), 14.11 (CH₃).

(S)-ethyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)-propanoate (1d). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and 1-naphthyl L-alanine ethyl ester phosphorochloridate (325mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (96:4) as an

eluant. The compound in this case was not completely pure, so a preparative TLC with DCM:MeOH (97:3) was used for further purification. The pure final compound was obtained in 23% yield (56mg) as a white solid. ³¹P NMR (CDCl₃): δ 3.30, 2.83. ¹H NMR (CDCl₃): δ 8.31 (1H, *bs*, NH), 7.91 (1H, *d*, *J* = 8.75Hz, H-6), 7.29-7.65 (7H, *m*, Naph), 6.88 (1H, *m*, H-1'), 6.24 (1H, *m*, H-2'), 5.82 (1H, *m*, H-3'), 5.42 (1H, *d*, *J* = 8.75Hz, H-5), 4.97 (1H, *m*, H-4'), 4.11 (2H, *m*, CH₂), 3.97 (2H, *m*, H-5'), 3.76 (1H, *t*, *J* = 9.22Hz, CH), 1.29 (3H, *d*, *J* = 7.38Hz, CH₃), 1.14 (3H, *m*, CH₃). ¹³C NMR (CDCl₃): δ 171.50 (CO-ester), 163.50 (C=O), 150.81 (C=O), 144.12 (C6), 126.12, 125.34, 125.06, 125.02, 124.89, 124.77, 124.67, 123.67, 123.15, 119.25 (10C-naphthyl), 100.90, 100.73 (C5), 80.08 (C1'), 82.96 (C4'), 65.20, 65.16 (C5'), 59.93, 58.86 (CH₂-ester), 48.42 (CH), 19.28 (CH₃), 12.19 (CH₃).

(S)-isopropyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (1e). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and phenyl L-alanine isopropyl ester phosphorochloridate (290.4mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 130mg (57%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 2.98, 2.62. ¹H NMR (CDCl₃): δ 9.19 (1H, *d*, *J* = 8.41Hz, NH), 7.50 (1H, *q*, *J* = 8.40Hz, H-6), 7.09-7.37 (5H, *m*, Phe), 6.34 (1H, *t*, *J* = 5.89Hz, H-1'), 8.91 (1H, *m*, H-2'), 5.84 (1H, *m*, H-3'), 5.62 (1H, *q*, *J* = 8.40Hz, H-5), 5.31 (1H, *m*, NH), 5.02 (2H, *m*, CH & H-3'), 4.28-4.40 (2H, *m*, CH & H-4'), 3.79-3.85 (2H, *m*, H-5'), 1.34 (3H, *dd*, *J* = 7.07Hz, *J* = 16.64Hz, CH₃), 1.22 (6H, *m*, 2xCH₃). HPLC (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 9.67, 9.89 min (2:3). ESI MS *m/z* (positive) 502.178 [M+Na].

(S)-isopropyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)propanoate (1f). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and 1-naphthyl L-alanine isopropyl ester phosphorochloridate (338mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (98:2) as an

eluant to afford 220mg (87%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 3.47, 3.05. ¹H NMR (CDCl₃): δ 9.45 (1H, *d*, *J* = 14.81Hz, NH), H-6), 7.74 (1H, *d*, *J* = 8.081Hz, H-6), 7.20-8.01 (7H, *m*, Naph), 7.15 (1H, *m*, H-1'), 6.89 (1H, *t*, *J* = 1.77Hz, H-2'), 6.19 (1H, *dd*, *J* = 6.01Hz, *J* = 18.64Hz, H-3'), 5.42 (1H, *d*, *J* = 8.08Hz, H-5), 2.92 (2H, *m*, H-4' & NH), 4.24 (1H, *m*, CH), 3.88-4.11 (2H, *m*, H-5'), 1.25 (3H, *d*, *J* = 6.84Hz, CH₃), 1.08 (9H, *m*, 2xCH₃). HPLC (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 10.91, 11.03 min (1:2). ESI MS *m/z* (positive) 552.138 [M+Na].

(*S*)-tert-butyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (1g). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and phenyl L-alanine *tert*-butyl ester phosphorochloridate (453.6mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 42.8mg (18%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 2.20, 1.89. ¹H NMR (CDCl₃): δ 8.29 (1H, *bs*, NH), 6.62 (1H, *dd*, *J* = 8.75Hz, H-6), 6.27-6.49 (5H, *m*, Ph), 6.13 (1H, *m*, H-1'), 5.45 (1H, *t*, *J* = 6.64Hz, H-2'), 4.89-5.05 (1H, *dd*, *J* = 5.32Hz, *J* = 39.02Hz, H-3'), 4.73 (1H, *q*, *J* = 8.75Hz, *J* = 18.94Hz, H-5), 4.14 (1H, *m*, H-4'), 3.54 (1H, *m*, CH), 3.46 (1H, *bs*, NH), 2.77-3.01 (1H, *m*, H-5'), 0.55 (9H, *d*, *J* = 8.46Hz, 3xCH₃), 0.48 (3H, *dd*, CH₃). ¹³C NMR (CDCl₃): δ 171.70 (CO-ester), 149.83 (C=O), 149.65 (C1''), 139.59, 139.28 (C6), 132.76, 132.57 (C3'), 128.97, 128.94 (C3''), 126.36, 126.13 (C2'), 124.25 (C4''), 119.13, 119.03, 119.04, 119.00 (C2''), 101.94, 101.74 (C5), 89.04 (88.84 (C1'), 84.10, 84.03, 83.99, 83.92 (C4'), 81.44 (C-ester), 76.43, 76.18, 75.92 (C5'), 49.94, 49.85 (CH-amino acid), 20.37, 20.17, 20.13 (3xCH₃), 14.40 (CH₃).

(*S*)-tert-butyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)-propanoate (1h). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and 1-naphthyl L-alanine *tert*-butyl ester phosphorochloridate (500mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (98:2) as an eluant to afford 54mg (21%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ

3.48, 3.08. **¹H NMR** (CDCl₃): δ 8.62 (1H, *bs*, NH), 7.62 (1H, *d*, *J* = 8.08Hz, H-6), 7.13-7.53 (7H, *m*, Naph), 6.90 (1H, *d*, *J* = 23.56Hz, H-1'), 6.20 (1H, *d*, *J* = 24.26Hz, H-2'), 5.63-5.72 (1H, *d*, *J* = 46.11Hz, H-3'), 5.45 (1H, *d*, *J* = 8.08Hz, H-5), 5.17 (1H, *m*, NH), 4.92 (1H, *m*, CH), 4.25 (1H, *m*, H-4'), 3.19-3.43 (2H, *m*, H-5'), 1.31 (9H, *d*, *J* = 12.88Hz, 3xCH₃), 1.19 (3H, *m*, CH₃). **HPLC** (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 11.67, 11.95 min (1:1). **ESI MS** *m/z* (positive) 566.169 [M+Na].

(S)-benzyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (1i). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and phenyl L-alanine benzyl ester phosphorochloridate (466mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant gave 180mg (31%) of the title compound as a white solid. **³¹P NMR** (CDCl₃): δ 2.80, 2.33. **¹H NMR** (CDCl₃): δ 8.60 (1H, *s*, NH), 7.36 (1H, *d*, *J* = 8.08Hz, H-6), 7.03-7.31 (10H, *m*, 2Ph), 6.91 (1H, *m*, H-1'), 6.24 (1H, *d*, *J* = 5.93Hz, H-2'), 5.74 (1H, *d*, *J* = 7.92Hz, H-3'), 5.51 (1H, *d*, *J* = 8.08Hz, H-5), 5.08 (2H, *d*, *J* = 3.43Hz, CH₂), 4.91 (1H, *m*, H-4'), 4.10-4.30 (2H, *m*, H-5'), 3.97 (1H, *m*, NH), 3.61 (1H, *t*, CH), 1.25 (3H, *d*, *J* = 7.10Hz, CH₃).

(S)-benzyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)-propanoate (1j). Prepared from d4U (3, 100mg, 0.475mmol, 1eq.), ^tBuMgCl (1.0M, 0.62mL, 0.617mM, 1.3eq.) and 1-naphthyl L-alanine benzyl ester phosphorochloridate (383mg, 0.95mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (98:2) as an eluant to afford 58mg (21%) of the title compound as a white solid. **³¹P NMR** (CDCl₃): δ 3.23, 2.65. **¹H NMR** (CDCl₃): δ 8.22 (1H, *bs*, NH), 7.56 (1H, *d*, *J* = 8.08Hz, H-6), 7.11-7.52 (12H, *m*, Ar), 6.89 (1H, *d*, *J* = 7.31Hz, H-1'), 6.15 (1H, *dd*, *J* = 5.36Hz, *J* = 28.62Hz, H-2'), 5.64-5.73 (1H, *dd*, H-3'), 4.40 (1H, *d*, *J* = 8.08Hz, H-5), 5.05 (2H, *s*, CH₂), 4.36 (1H, *t*, *J* = 9.15Hz, H-4'), 4.24 (1H, *m*, CH), 4.06 (1H, *m*, NH), 3.47-3.76 (2H, *m*, H-5'), 1.23 (3H, *dd*, *J* = 7.02Hz, *J* = 17.43Hz, CH₃). **HPLC** (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 12.19 min. **ESI MS** *m/z* (positive) 600.151 [M+Na].

(S)-methyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (2a).

Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and phenyl L-alanine methyl ester phosphorochloridate (214mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 43.2mg (20%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 2.70, 2.92. ¹H NMR (CDCl₃): δ 9.27 (1H, *s*, NH), 7.66 (1H, *q*, *J* = 8.10Hz, H-6), 7.06-7.24 (5H, *m*, Ph), 6.00 (1H, *m*, H-1'), 6.23 (1H, *q*, *J* = Hz, H-5), 4.34 (1H, *m*, H-4'), 4.14-4.26 (1H, *m*, H-5'), 3.89-4.06 (1H, *m*, CH), 3.62 (3H, *s*, CH₃), 3.41 (1H, *q*, *J* = 7.59Hz, NH), 2.24-2.43 (1H, *m*, H-2'), 2.03 (1H, *m*, H-3'), 1.76-1.75 (1H, *m*, H-2'), 1.32 (3H, *t*, *J* = 7.22Hz, CH₃). ¹³C NMR (CDCl₃): δ 174.00, 173.85 (CO-ester), 163.43, 163.41 (C=O), 150.60, 150.55 (C1''), 150.38 (C=O), 139.79, 139.78 (C6), 129.81, 129.78 (C3''), 125.15, 125.13 (C4''), 120.04, 120.02, 120.00, 119.98 (C2''), 102.11, 102.05 (C5), 86.36, 86.10 (C4), 79.01, 78.97, 87.94, 78.90 (C1'), 77.30, 77.05, 76.79 (C5'), 52.59, 52.58 (CH₃O), 50.34, 50.16 (CH), 32.27, 32.20 (C2'), 25.30, 25.17 (C3'), 15.26 (CH₃). HPLC (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 8.65 min. ESI MS *m/z* (positive) 476.178 [M+Na].

(S)-methyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)-propanoate (2b).

Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and 1-naphthyl L-alanine methyl ester phosphorochloridate (403mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 73.5mg (31%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 3.76, 3.83. ¹H NMR (CDCl₃): δ 8.09 (1H, *bs*, NH), 7.76 (1H, *d*, *J* = 8.10Hz, H-6), 7.34-7.60 (7H, *m*, Naph), 5.73 (1H, *m*, H-1'), 5.39 (1H, *d*, *J* = 8.10Hz, H-5), 4.33 (1H, *m*, H-4'), 4.18 (1H, *m*, NH), 4.10 (1H, *m*, CH), 3.52 (2H, *m*, H-5'), 2.21-2.29 (1H, *m*, H-2'), 1.91 (1H, *m*, H-3'), 1.78-1.89 (1H, *m*, H-2'), 1.27 (3H, *t*, *J* = 8.78Hz, CH₃).

(S)-ethyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (2c). Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and phenyl L-alanine ethyl ester phosphorochloridate (208mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 48.3mg (22%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 2.81, 3.14. ¹H NMR (CDCl₃): δ 9.50 (1H, *bs*, NH), 7.58 (1H, *d*, *J* = 8.10, Hz, H-6), 7.03-7.23 (5H, *m*, Ph), 6.00 (1H, *m*, H-1'), 5.56 (1H, *d*, *J* = 8.10Hz, H-5), 4.33 (1H, *m*, H-4'), 4.16-4.23 (1H, *m*, H-5'), 4.10 (1H, *m*, CH), 3.96 (2H, *m*, CH₂), 3.41 (1H, *q*, *J* = Hz, NH), 2.24-2.38 (1H, *m*, H-2'), 2.01 (1H, *m*, H-3'), 1.77-1.93 (1H, *m*, H-2'), 1.27 (3H, *t*, *J* = 6.52Hz, CH₃), 1.14 (3H, *m*, CH₃). ¹³C NMR (CDCl₃): δ 173.58, 173.52, 173.45, 173.40 (CO-ester), 163.54, 163.52 (C=O), 150.62, 150.57 (C=O), 150.44 (C1''), 139.77 (C6), 129.79, 129.76, 129.62 (C3''), 125.12, 125.09, 124.77 (C4''), 120.13, 120.05, 120.01, 119.98 (C2''), 102.12, 102.06 (C5), 86.32, 86.08 (C1'), 78.99, 78.96, 78.93, 78.89 (C4'), 67.30, 67.26, 67.02 (C5'), 61.66, 61.49 (CH₂), 50.65, 50.40, 50.21 (CH), 32.27, 32.20 (C2'), 25.30, 25.17 (C3'), 20.99, 20.95, 20.90 (CH₃-amino acid), 14.11, 14.09 (CH₃-ester). HPLC (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 8.85 min. ESI MS *m/z* (positive) 490.195 [M+Na].

(S)-tert-butyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (2d). Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and phenyl L-alanine *tert*-butyl ester phosphorochloridate (300mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 49.2mg (21%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 3.00, 3.08. ¹H NMR (CDCl₃): δ 9.53 (1H, *bs*, NH), 7.64 (1H, *d*, *J* = 8.10Hz, H-6), 7.13-7.31 (5H, *m*, Ph), 6.07 (1H, *m*, H-1'), 5.61 (1H, *d*, *J* = 8.10Hz, H-5), 4.43 (1H, *m*, H-4'), 3.90-4.23 (2H, *m*, H-5'), 3.47 (1H, *s*, NH), 2.31-2.41 (1H, *m*, H-2'), 2.07 (1H, *m*, H-3'), 1.87-1.99 (1H, *m*, H-2'), 1.46 (9H, *q*, *J* = 1.92Hz, 3xCH₃), 1.32 (3H, *d*, *J* = 1.28Hz, CH₃). ¹³C NMR (CDCl₃): δ 172.69, 172.62, 172.55 (CO-ester), 163.49 (C=O), 150.66, 150.61 (C=O),

150.44 (C1''), 139.74 (C6), 129.78, 129.75, 129.61 (C3''), 125.05 (C4''), 120.06, 120.04, 120.02, 120.00 (C2''), 102.12, 102.08 (C5), 86.31, 86.08 (C1'), 78.98, 78.91 (C4'), 67.22, 67.18, 66.97, 66.93 (C5'), 65.82 (CH₂), 50.89, 50.74, 50.67 (CH), 32.31, 32.22 (C2'), 27.92, 27.91 (3xCH₃), 25.35, 25.17 (C3'), 21.17, 21.13, 21.07, 21.03 (CH₃-amino acid), 14.11, 14.09 (CH₃-ester). **HPLC** (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 10.19 min. **ESI MS** m/z (positive) 518.227 [M+Na].

(S)-benzyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (2e).

Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and phenyl L-alanine benzyl ester phosphorochloridate (332mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 53.4g (21%) of the title compound as a white solid. **³¹P NMR** (CDCl₃): δ 2.62, 2.83. **¹H NMR** (CDCl₃): δ 9.05 (1H, *bs*, NH), 7.53 (1H, *d*, *J* = 8.09Hz, H-6), 7.03-7.31 (10H, *m*, Ph), 5.98 (1H, *m*, H-1'), 5.56 (1H, *d*, *J* = 8.09Hz, H-5), 5.03 (2H, *s*, CH₂), 4.30 (1H, *m*, H-4'), 4.18 (2H, *m*, H-5'), 4.10 (1H, *m*, CH), 3.86 (1H, *m*, NH), 2.25-2.36 (1H, *m*, H-2'), 1.99 (1H, *m*, H-3'), 1.79-1.96 (1H, *m*, H-2'), 1.32 (3H, *t*, *J* = 6.95Hz, CH₃). **¹³C NMR** (CDCl₃): δ 173.38 (CO-ester), 163.26 (C=O), 150.51, 150.30 (C=O), 150.27 (C1''), 139.74 (C6), 135.16, 129.82, 129.78, 128.68, 128.65, 128.60, 128.53, 128.29, 128.27, 125.16, (10C-Ar), 102.10, 102.02 (C5), 86.31, 86.09 (C1'), 78.93, 78.87 (C4'), 67.34, 67.27, 67.23, 67.06, 67.02 (C5'), 50.75, 50.48, 50.29 (CH₂), 32.25, 32.17 (CH), 25.23, 25.16 (C2'), 21.02, 20.96, 20.91, 20.86 (C3'), 14.18 (CH₃-ester).


(S)-benzyl 2-((((2S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphorylamino)-propanoate (2f).


Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and 1-naphthyl L-alanine benzyl ester phosphorochloridate (379mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 44.3mg (16%) of the title compound as a white solid. **³¹P NMR** (CDCl₃): δ 3.08, 3.38. **¹H NMR** (CDCl₃): δ 9.38 (1H, *bs*, NH), 7.98 (1H, *d*, *J* = 8.08Hz, H-6),


7.22-7.71 (12H, *m*, Ar), 5.91 (1H, *m*, H-1'), 5.39 (1H, *d*, *J* = 8.08Hz, H-5), 4.98 (1H, *s*, NH), 4.27 (1H, *m*, H-4'), 4.06 (1H, *m*, CH), 3.96-4.20 (2H, *m*, H-5'), 3.40 (2H, *s*, NH), 2.17-2.22 (1H, *m*, H-2'), 1.81 (1H, *m*, H-3'), 1.64-1.72 (1H, *m*, H-2'), 1.27 (3H, *m*, CH₃). ¹³C NMR (CDCl₃): δ 173.45, 173.40, 173.23, 173.18 (CO-ester), 163.40 (C=O), 150.38 (C=O), 134.77, 134.74, 128.67, 128.61, 128.58, 128.48, 128.40, 128.29, 128.22, 128.13, 127.97, 126.97 (12C-Ar), 102.16, 102.10 (C5), 86.18, 85.90 (C1'), 78.71, 78.66, 78.60 (C4'), 77.33, 77.08, 76.83 (C5'), 67.51, 67.47, 67.33, 67.29 (CH₂), 50.56, 50.42 (CH), 32.04, 31.85 (C2'), 25.26, 25.15 (C3'), 15.27 (CH₃-amino acid). HPLC (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 11.05 min. ESI MS *m/z* (positive) 602.230 [M+Na].

(S)-benzyl 2-((((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-tetrahydrofuran-2-yl)methoxy)(4-methoxynaphthalen-1-yl)oxy)phosphorylamino)propanoate (2g). Prepared from ddU (4, 100mg, 0.471mmol, 1 eq.), ^tBuMgCl (1.0M, 0.7mL, 0.61mM, 1.3eq.) and 1-naphthyl L-alanine benzyl ester phosphorochloridate (408mg, 0.94mM, 2eq.) in THF (7mL). Column chromatography using DCM:MeOH (97:3) as an eluant to afford 51.2mg (18%) of the title compound as a white solid. ³¹P NMR (CDCl₃): δ 3.41, 3.43. ¹H NMR (CDCl₃): δ 8.87 (1H, *d*, NH), 7.91 (1H, *d*, *J* = 8.09Hz, H-6), 7.23-7.51 (11H, *m*, Ar), 5.93 (1H, *d*, *J* = 9.71Hz, H-1'), 5.41 (1H, *d*, *J* = 8.09Hz, H-5), 5.01 (2H, *s*, CH₂), 4.26 (1H, *m*, H-4'), 4.03-4.23 (2H, *m*, H-5'), 3.87 (1H, *m*, CH), 3.82 (1H, *m*, NH), 2.16-2.23 (1H, *m*, H-2'), 1.66-1.73 (1H, *m*, H-3'), 1.19-1.59 (1H, *m*, H-2'), 1.22 (2H, *dd*, *J* = 7.09Hz, *J* = 10.41Hz, CH₃). ¹³C NMR (CDCl₃): δ 173.41, 173.40, 173.39 (CO-ester), 163.00 (C=O), 152.73 (C=O), 150.18, 139.59, 139.50, 128.27, 128.62, 128.59, 128.49, 128.28, 128.21, 127.06, 127.01, 126.33, 115.03, 102.81, 102.72 (Ar), 102.15, 102.08 (C5), 86.20, 85.95 (C1'), 78.73, 78.67 (C4'), 77.28, 77.03, 76.78 (C5'), 67.46, 67.42, 67.33, 67.24 (CH₂), 55.75 (CH₃OAr), 50.55, 50.41 (CH), 32.03, 31.91 (C2'), 25.27, 25.16 (C3'), 21.09, 21.05, 20.97 (CH₃-amino acid). HPLC (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 11.32 min. ESI MS *m/z* (positive) 632.243 [M+Na].

Ammonium((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,5-dihydrofuran-2-yl)methyl phosphate. Under an argon atmosphere, to a suspension of 2',3'-didehydro-2',3'-dideoxyuridine (640mg, 1.1mmol) in triethyl phosphate (5mL), POCl₃ (0.32mL, 1.50mmol) was added to 0°C. the reaction was stirred at the same temperature, i.e. 0°C, for 2hr. After this time TLC (EtOAc:MeOH, 9:1 and iPrOH:NH₃:H₂O, 7:1:2) showed the disappearance of the starting material. A solution of NH₄CO₃ (0.4M) was then added until the effervescence stopped. After 10minutes the mixture was concentrated under reduced pressure, the residue was dissolved in water (10mL) and filtered off. The filtrate was subsequently purified by column chromatography (iPrOH:NH₃:H₂O; 9:1:2). The appropriate fractions were collected and the solvent was removed *in vacuo* to yield a white salt (100mg). ³¹P NMR (D₂O): δ 1.46. ¹H NMR (D₂O): δ 7.73 (1H, *d*, *J* = 8.08Hz, H-6), 6.90 (1H, *d*, H-1'), 6.43 (1H, *m*, H-2'), 5.92 (1H, *m*, H-3'), 5.82 (1H, *d*, *J* = 8.08Hz, H-5), 5.05 (1H, *m*, H-4'), 3.92 (2H, *m*, H-5'). ¹³C NMR (D₂O): δ 166.46 (C=O), 152.13 (C=O), 65.74 (C-5'), 142.90 (C-6), 134.07 (C-2'), 125.08 (C-3'), 102.11 (C-5), 90.20 (C-1'), 86.00 (C-4'), 65.78 (C5'). **HPLC** (H₂O/CH₃CN from 100/0 to 0/100 in 20min): Rt 1.60 min.






























Current Data Parameters
NAME CM-jm-ym16_2nd
EXPNO 1
PROCNO 1
F2 - Acquisition Parameters
Date_ 20060505
Time 15.19
INSTRUM Avance500
PROBHD 5 mm QNP 1H/13
PULPROG zgpg30
TD 65536
FIDRES 0.17632 Hz
AQ 3.719923 sec
RG 320
SW 48.400 use
DE 12.00 use
TE 298.1 K
D1 1.0000000 sec
TD0 1
===== CHANNEL f1 =====
NUC1 1H
P1 12.00 use
PL1 -1.00 dB
SFO1 500.1300885 MHz
F2 - Processing parameters
SI 32768
SF 500.1300465 MHz
WDW EM
SSB 0
GB 0
PC 1.00






1d





Current Data Parameters
NAME: CH₂-pyridine-2-yl
PULPROG: zgpg30
PROCNO: 1
F2 - Acquisition Parameters
Date_ : 20080521
Time : 11.21
INSTRUM: spect
PROBHD: 5 mm QNP1H
PULPROG: zgpg30
TD: 65536
SFO: 500.130465
AQ: 0.18000000
RG: 1024
WDW: EM
SSB: 0
LB: 3.00 Hz
GB: 0
PC: 1.40
F1 - Processing parameters
SI: 32768
SF: 500.130465 MHz
WDW: EM
SSB: 0
LB: 3.00 Hz
GB: 0
PC: 1.40


Current Data Parameters
NAME: CH₂-pyridine-2-yl
PULPROG: zgpg30
PROCNO: 1
F2 - Acquisition Parameters
Date_ : 20080521
Time : 11.21
INSTRUM: spect
PROBHD: 5 mm QNP1H
PULPROG: zgpg30
TD: 65536
SFO: 500.130465
AQ: 0.18000000
RG: 1024
WDW: EM
SSB: 0
LB: 3.00 Hz
GB: 0
PC: 1.40
F1 - Processing parameters
SI: 32768
SF: 500.130465 MHz
WDW: EM
SSB: 0
LB: 3.00 Hz
GB: 0
PC: 1.40


















19








































































































2g

